Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison.

Ann Hematol · 2026 · PMC12924849 · PMID 41721879

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

After adjustment for cross-trial differences, the MAIC results showed a favorable trend for momelotinib vs.

also in 993 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.